![Jonathan Zalevsky](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jonathan Zalevsky
Directeur Technique/Scientifique/R&D chez
NEKTAR THERAPEUTICS
Fortune : 689 457 $ au 31/07/2026
Profil
Jonathan Zalevsky is currently Director at InveniAI LLC since 2017, Independent Director at Invea Therapeutics, Inc. since 2021, and Chief Research & Development Officer, Senior VP at Nektar Therapeutics since 2019.
Former roles include Director at ReAlta Life Sciences, Inc. from 2019 to 2023 and Global VP & Head-Inflammation Drug Discovery Unit at Takeda Pharmaceuticals U.S.A., Inc. Education includes a doctorate from The University of California, San Francisco and an undergraduate degree from the University of Colorado Boulder.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NEKTAR THERAPEUTICS 0,03 % | 24/07/2026 | 9 756 ( 0,03 % ) | 689 457 $ | 31/07/2026 |
Postes actifs de Jonathan Zalevsky
| Sociétés | Poste | Début |
|---|---|---|
| NEKTAR THERAPEUTICS | Directeur Technique/Scientifique/R&D | 01/07/2015 |
Invea Therapeutics, Inc.
 Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs | Directeur/Membre du Conseil | 01/11/2021 |
Inveniai LLC
 Inveniai LLC Information Technology ServicesTechnology Services InveniAI LLC applies artificial intelligence and machine learning to accelerate drug discovery and development, focusing on diseases with unmet medical needs. The private company is based in Guilford, CT. The company leverages its proprietary AI platform, AlphaMeld®, to integrate scientific, medical, chemical, and biological data for generating hypotheses and prioritizing biological targets and treatment modalities. AlphaMeld® is used to decode complex pathways, such as the gut-brain axis and inflammasome pathways, to develop therapies for chronic inflammatory gastrointestinal diseases like irritable bowel syndrome and inflammatory bowel disease, with the goal of improving localized efficacy and reducing systemic side effects. InveniAI also offers ChatAlphaMeld, a generative AI assistant that supports literature review, predictive analytics, and clinical trial design while maintaining data privacy and content validation. The company collaborates with pharmaceutical partners and has participated in numerous biopharma collaborations. The CEO of the company is Krishnan Nandabalan. | Directeur/Membre du Conseil | 01/01/2017 |
Anciens postes connus de Jonathan Zalevsky
| Sociétés | Poste | Fin |
|---|---|---|
ReAlta Life Sciences, Inc.
 ReAlta Life Sciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops novel class of drugs with dual-targeting therapeutic capabilities | Directeur/Membre du Conseil | 01/12/2023 |
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Corporate Officer/Principal | - |
Formation de Jonathan Zalevsky
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
55
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Nektar Therapeutics
 Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
University of Colorado Boulder
 University of Colorado Boulder Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ReAlta Life Sciences, Inc.
ReAlta Life Sciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops novel class of drugs with dual-targeting therapeutic capabilities | Health Technology |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs | Health Technology |
Inveniai LLC
Inveniai LLC Information Technology ServicesTechnology Services InveniAI LLC applies artificial intelligence and machine learning to accelerate drug discovery and development, focusing on diseases with unmet medical needs. The private company is based in Guilford, CT. The company leverages its proprietary AI platform, AlphaMeld®, to integrate scientific, medical, chemical, and biological data for generating hypotheses and prioritizing biological targets and treatment modalities. AlphaMeld® is used to decode complex pathways, such as the gut-brain axis and inflammasome pathways, to develop therapies for chronic inflammatory gastrointestinal diseases like irritable bowel syndrome and inflammatory bowel disease, with the goal of improving localized efficacy and reducing systemic side effects. InveniAI also offers ChatAlphaMeld, a generative AI assistant that supports literature review, predictive analytics, and clinical trial design while maintaining data privacy and content validation. The company collaborates with pharmaceutical partners and has participated in numerous biopharma collaborations. The CEO of the company is Krishnan Nandabalan. | Technology Services |
